Barclays PLC Lowers Position in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Barclays PLC cut its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 73.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,173 shares of the company’s stock after selling 3,263 shares during the quarter. Barclays PLC’s holdings in VanEck Pharmaceutical ETF were worth $112,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of PPH. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of VanEck Pharmaceutical ETF by 51.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 248,473 shares of the company’s stock worth $23,565,000 after acquiring an additional 84,273 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of VanEck Pharmaceutical ETF by 33.6% in the third quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock worth $22,322,000 after acquiring an additional 59,025 shares during the period. Miller Investment Management LP boosted its stake in shares of VanEck Pharmaceutical ETF by 13.4% in the third quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock worth $19,722,000 after acquiring an additional 24,446 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of VanEck Pharmaceutical ETF by 1.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock worth $14,641,000 after acquiring an additional 2,694 shares during the period. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management bought a new position in shares of VanEck Pharmaceutical ETF in the third quarter worth about $8,743,000.

VanEck Pharmaceutical ETF Trading Up 0.0 %

Shares of VanEck Pharmaceutical ETF stock opened at $87.07 on Thursday. The stock has a 50 day moving average of $88.54 and a 200 day moving average of $92.42. VanEck Pharmaceutical ETF has a 12 month low of $83.60 and a 12 month high of $99.51. The firm has a market cap of $599.91 million, a PE ratio of 21.04 and a beta of 0.72.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently declared a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were paid a dividend of $0.411 per share. The ex-dividend date of this dividend was Friday, December 27th. This is a positive change from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.